iTeos Therapeutics Quote - ITOS

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

7.54

Bid

7.43

Offer

7.80

Volume

229,038

7.4909 Day's Range 7.83

7.09 52 Week Range 18.75

Market Cap

275.466M

Previous Close

7.68

Open

7.81

Last Trade

7.54

Last Trade Time

Financial Volume

US$ 1,751,606

VWAP

7.6477

Average Volume (3m)

432,816

Shares Outstanding

36,533,918

Dividend Yield

PE Ratio

-2.45

Earnings Per Share (EPS)

-3.08

Revenue

12.6M

Net Profit

-112.64M

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.iteostherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was US$7.68. Over the last year, iTeos Therapeutics shares have traded in a share price range of US$ 7.09 to US$ 18.75.

iTeos Therapeutics currently has 36,533,918 shares in issue. The market capitalisation of iTeos Therapeutics is US$280.58 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -2.45.

Form 8-K - Current report

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L...

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.08	-1.0498687664	7.62	7.94	7.39	193119	7.58009674	CS
4	-0.425	-5.3358443189	7.965	8.31	7.39	272215	7.80163047	CS
12	-1.47	-16.3152053274	9.01	9.71	7.09	432816	7.95352193	CS
26	-10.07	-57.1834185122	17.61	18.13	7.09	536326	10.51890758	CS
52	-2.41	-24.2211055276	9.95	18.75	7.09	449929	12.04388898	CS
156	-27.33	-78.3768282191	34.87	37.88	7.09	395445	16.11668132	CS
260	-12.16	-61.7258883249	19.7	52.43	7.09	360849	20.20593534	CS

ITOS - Frequently Asked Questions (FAQ)

What is the current iTeos Therapeutics share price?

The current share price of iTeos Therapeutics is US$ 7.54

How many iTeos Therapeutics shares are in issue?

iTeos Therapeutics has 36,533,918 shares in issue

What is the market cap of iTeos Therapeutics?

The market capitalisation of iTeos Therapeutics is USD 280.58M

What is the 1 year trading range for iTeos Therapeutics share price?

iTeos Therapeutics has traded in the range of US$ 7.09 to US$ 18.75 during the past year

What is the PE ratio of iTeos Therapeutics?

The price to earnings ratio of iTeos Therapeutics is -2.45

What is the cash to sales ratio of iTeos Therapeutics?

The cash to sales ratio of iTeos Therapeutics is 21.9

What is the reporting currency for iTeos Therapeutics?

iTeos Therapeutics reports financial results in USD

What is the latest annual turnover for iTeos Therapeutics?

The latest annual turnover of iTeos Therapeutics is USD 12.6M

What is the latest annual profit for iTeos Therapeutics?

The latest annual profit of iTeos Therapeutics is USD -112.64M

What is the registered address of iTeos Therapeutics?

The registered address for iTeos Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the iTeos Therapeutics website address?

The website address for iTeos Therapeutics is www.iteostherapeutics.com

Which industry sector does iTeos Therapeutics operate in?

iTeos Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	731.1M
REBNReborn Coffee Inc	US$ 3.31 (63.05%)	55.54M
FCUVFocus Universal Inc	US$ 5.87 (56.62%)	1.73M
SOPASociety Pass Inc	US$ 1.54 (56.50%)	13.87M
CYCNCyclerion Therapeutics Inc	US$ 3.92 (54.33%)	82.57M
ENVBEnveric Biosciences Inc	US$ 2.0899 (-46.41%)	1.58M
NIVFNewGenIvf Group Ltd	US$ 0.1489 (-42.51%)	14.91M
GLSTGlobal Star Acquisition Inc	US$ 8.83 (-39.10%)	23.93k
PRPHProPhase Labs Inc	US$ 0.2633 (-38.02%)	900.48k
SPGCSacks Parente Golf Inc	US$ 0.5601 (-37.86%)	7.42M
TCTMTCTM Kids IT Education Inc	US$ 0.764 (321.87%)	731.1M
NVDANVIDIA Corporation	US$ 120.07 (-3.67%)	388.5M
RIMEAlgorhythm Holdings Inc	US$ 0.02565 (5.12%)	341.8M
CLEUChina Liberal Education Holdings Ltd	US$ 0.1938 (30.77%)	237.15M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0355 (-11.25%)	236.44M